Theranexus SA
THX Pharma Société Anonyme, a biopharmaceutical company, engages in the development of drug candidates for the treatment of central nervous system disorders. It is involved in the development of Batten-1, an initial drug candidate currently under Phase ½ clinical study for Batten disease. The company was formerly known as Theranexus Société Anonyme and change its name to THX Pharma Société Anonym… Read more
Theranexus SA (ALTHX) - Net Assets
Latest net assets as of June 2025: €-1.89 Million EUR
Based on the latest financial reports, Theranexus SA (ALTHX) has net assets worth €-1.89 Million EUR as of June 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€4.53 Million) and total liabilities (€6.42 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €-1.89 Million |
| % of Total Assets | -41.69% |
| Annual Growth Rate | N/A |
| 5-Year Change | -116.11% |
| 10-Year Change | N/A |
| Growth Volatility | 6529.81 |
Theranexus SA - Net Assets Trend (2015–2024)
This chart illustrates how Theranexus SA's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Theranexus SA (2015–2024)
The table below shows the annual net assets of Theranexus SA from 2015 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | €-1.66 Million | -174.58% |
| 2023-12-31 | €2.22 Million | -61.22% |
| 2022-12-31 | €5.73 Million | -43.74% |
| 2021-12-31 | €10.18 Million | -0.98% |
| 2020-12-31 | €10.28 Million | +3.08% |
| 2019-12-31 | €9.98 Million | -25.61% |
| 2018-12-31 | €13.41 Million | -28.33% |
| 2017-12-31 | €18.71 Million | +20723.82% |
| 2016-12-31 | €89.85K | -94.64% |
| 2015-12-31 | €1.68 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Theranexus SA's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 124650300.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | €2.13 Million | % |
| Total Equity | €-1.66 Million | 100.00% |
Theranexus SA Competitors by Market Cap
The table below lists competitors of Theranexus SA ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Nhoa SA
PA:NHOA
|
$27.49 Million |
|
Jinli Group Holdings Ltd
TW:8429
|
$27.50 Million |
|
IDIS Holdings Co. Ltd
KQ:054800
|
$27.51 Million |
|
WFE Technology Corporation
TWO:6474
|
$27.51 Million |
|
P.A. Resources Bhd
KLSE:7225
|
$27.48 Million |
|
LGL Group Inc
NYSE MKT:LGL
|
$27.48 Million |
|
Pan Brothers Tbk
JK:PBRX
|
$27.48 Million |
|
SFOODS
HE:SFOODS
|
$27.44 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Theranexus SA's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 2,221,548 to -1,656,913, a change of -3,878,461 (-174.6%).
- Net loss of 1,765,156 reduced equity.
- Share repurchases of 337,500 reduced equity.
- New share issuances of 337,495 increased equity.
- Other comprehensive income increased equity by 6,827,952.
- Other factors decreased equity by 8,941,252.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | €-1.77 Million | -106.53% |
| Share Repurchases | €337.50K | -20.37% |
| Share Issuances | €337.50K | +20.37% |
| Other Comprehensive Income | €6.83 Million | +412.09% |
| Other Changes | €-8.94 Million | -539.63% |
| Total Change | €- | -174.58% |
Book Value vs Market Value Analysis
This analysis compares Theranexus SA's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2015-12-31 | €1.89 | €2.98 | x |
| 2016-12-31 | €0.10 | €2.98 | x |
| 2017-12-31 | €6.00 | €2.98 | x |
| 2018-12-31 | €4.13 | €2.98 | x |
| 2019-12-31 | €2.63 | €2.98 | x |
| 2020-12-31 | €2.15 | €2.98 | x |
| 2021-12-31 | €1.77 | €2.98 | x |
| 2022-12-31 | €1.07 | €2.98 | x |
| 2023-12-31 | €0.29 | €2.98 | x |
| 2024-12-31 | €-0.19 | €2.98 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Theranexus SA utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.00%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -77.30%
- • Asset Turnover: 0.61x
- • Equity Multiplier: 0.00x
- Recent ROE (0.00%) is above the historical average (-247.90%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2015 | -30.93% | -92.39% | 0.21x | 1.63x | €-686.32K |
| 2016 | -1766.01% | -1752.11% | 0.03x | 32.06x | €-1.60 Million |
| 2017 | -11.30% | -1430.55% | 0.01x | 1.09x | €-3.99 Million |
| 2018 | -41.19% | -4778.40% | 0.01x | 1.46x | €-6.59 Million |
| 2019 | -59.14% | -989.58% | 0.04x | 1.63x | €-6.52 Million |
| 2020 | -54.99% | -1628.46% | 0.02x | 2.00x | €-5.67 Million |
| 2021 | -93.44% | -1353889.37% | 0.00x | 1.94x | €-9.02 Million |
| 2022 | -114.65% | -1582.80% | 0.03x | 2.10x | €-7.14 Million |
| 2023 | -307.35% | -2304.16% | 0.04x | 3.26x | €-7.05 Million |
| 2024 | 0.00% | -77.30% | 0.61x | 0.00x | €-1.60 Million |
Industry Comparison
This section compares Theranexus SA's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $11,397,324
- Average return on equity (ROE) among peers: -51.25%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Theranexus SA (ALTHX) | €-1.89 Million | -30.93% | N/A | $27.49 Million |
| Abionyx Pharma SA (ABNX) | $8.89 Million | -56.01% | 1.06x | $72.33 Million |
| Abivax SA (ABVX) | $56.72 Million | -25.23% | 0.07x | $3.97 Billion |
| Adocia (ADOC) | $-6.91 Million | 0.00% | 0.00x | $84.57 Million |
| Aelis Farma SA (AELIS) | $898.00K | 63.92% | 30.53x | $5.01 Million |
| Acticor Biotech SAS (ALACT) | $-4.04 Million | 0.00% | 0.00x | $2.13 Million |
| NicOx S.A. (ALCOX) | $21.41 Million | -97.51% | 1.47x | $28.49 Million |
| Advicenne (ALDVI) | $-1.67 Million | 0.00% | 0.00x | $15.84 Million |
| ALGAE (ALGAE) | $32.76 Million | -39.31% | 0.56x | $29.13 Million |
| Genoway (ALGEN) | $5.23 Million | 9.60% | 1.10x | $23.45K |
| Integragen (ALINT) | $691.87K | -367.93% | 7.36x | $424.10K |